RESUMEN
Background: We have previously reported that immunization with GRA2 antigen of Toxoplasma gondii induces protective immunity in CBA/J (H2k) and BALB/c mice (H2d). We aimed to examine whether immunization of a distinct strain of rodent with recombinant dense granule antigens (GRA2) combined with monophosphorryl lipid A (MPL) adjuvant elicits protective immune response against T. gondii. Methods: C57BL/6 (H2b haplotype) mice were immunized with GRA2, formulated in MPL adjuvant. Results: Strong humoral response, predominantly of IgG1 subclass and cellular response, IFN-γ, was detected at three weeks post immunization. Mice immunized with GRA2 had significantly (p < 0.01) fewer brain cysts than those in the adjuvant group, upon challenge infection. Despite the production of a strong antibody response, IFN-γ production and brain cyst reduction were not significant when the immunized mice were infected four months after the immunization. Conclusion: We can conclude that GRA2 immunization partially protects against T. gondii infection in C57BL/6 mice, though the potency and longevity of this antigen as a standalone vaccine may vary in distinct genetic backgrounds. This observation further emphasizes the utility of GRA2 for incorporation into a multi-antigenic vaccine against T. gondii.
RESUMEN
There is still no human vaccine against Toxoplasma gondii (T. gondii), as one of the most successful parasites. In present study, we designed a subunit vaccine composed of recombinant SAG1 (rSAG1) and recombinant GRA2 (rGRA2) proteins. In order to improve the induced immune responses, rSAG1 and rGRA2 were adsorbed on Poly (DL-lactide-co-glycolide) (PLGA) microspheres (MS) prepared by double emulsion solvent evaporation method. BALB/c mice were subcutaneously vaccinated by rSAG1-adsorbed PLGA MS (rSAG1-PLGA), rGRA2-adsorbed PLGA MS (rGRA2-PLGA), and the mixture of both formulations (rSAG1/rGRA2-PLGA), twice with a 3-week interval. PLGA MS characteristics, protein release, cellular and humoral immune responses, and protection against acute toxoplasmosis were evaluated. All vaccinated mice induced significantly partial protection and longer survival times associated with higher IFN-γ/IL-10 ratio and higher amount of Toxoplasma-specific IgG antibodies compared to control groups. Interestingly, the synergistic effect of rSAG1 and rGRA2 in eliciting more potent cellular and humoral responses and consequently higher protection in comparison to single antigen was confirmed. This study introduces the mixture of rSAG1 and rGRA2 (derived from different stages of Toxoplasma life-cycle) formulated in PLGA MS as a promising candidate in vaccine development against T. gondii.
Asunto(s)
Antígenos de Protozoos/inmunología , Proteínas Protozoarias/inmunología , Vacunas Antiprotozoos , Toxoplasma/inmunología , Adsorción , Animales , Antígenos de Protozoos/administración & dosificación , Portadores de Fármacos , Sinergismo Farmacológico , Femenino , Humanos , Inmunoglobulina G/sangre , Interferón gamma/análisis , Interleucina-10/análisis , Ácido Láctico , Ratones , Ratones Endogámicos BALB C , Microesferas , Ácido Poliglicólico , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Embarazo , Proteínas Protozoarias/administración & dosificación , Vacunas Antiprotozoos/administración & dosificación , Vacunas Antiprotozoos/inmunología , Conejos , Distribución Aleatoria , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Bazo/citología , Bazo/inmunología , Toxoplasmosis Animal/prevención & control , Vacunas de Subunidad/inmunologíaRESUMEN
Recombinant antigens are increasingly applied to replace native antigens in serological tests. Surface antigen 1 (SAG1) is a highly immunogenic antigen and probably represents the most explored and used antigen of Toxoplasma gondii for development of serological test kits. The presence of six disulfide bridges in its structure makes SAG1 a highly conformational protein. In fact, antigenicity of SAG1 is greatly dependent on proper disulfide bonding and folding. In-vitro refolding of SAG1 inclusion bodies, produced in Escherichia coli, was reported to result in soluble and antigenic protein. We produced SAG1 in E. coli and highly purified it by a single denaturing immobilized metal affinity chromatography. Refolding of denatured SAG1 was performed by (a) dialysis in the presence of reduced/oxidized glutathione, (b) drop-wise dilution and (c) drop-wise dilution in the presence of CuSo4. Refolding in the presence of oxido-shuffling reagent was much more efficient in producing presumably correctly-folded and highly antigenic SAG1 as demonstrated by non-reducing SDS-gel electrophoresis, ELISA, Western blotting and reversed-phase HPLC. An IgG ELISA developed using SAG1 refolded in the presence of oxido-shuffling reagent displayed high sensitivity and specificity for detection of Toxoplasma IgG antibodies in pregnant women.
Asunto(s)
Antígenos de Protozoos/inmunología , Ensayo de Inmunoadsorción Enzimática/métodos , Inmunoglobulina G/inmunología , Proteínas Protozoarias/inmunología , Toxoplasma/inmunología , Anticuerpos Antiprotozoarios/inmunología , Antígenos de Protozoos/genética , Antígenos de Protozoos/metabolismo , Antígenos de Superficie/inmunología , Escherichia coli/genética , Escherichia coli/metabolismo , Femenino , Humanos , Embarazo , Proteínas Protozoarias/genética , Proteínas Protozoarias/metabolismo , Sensibilidad y Especificidad , Pruebas Serológicas/métodos , Toxoplasma/genética , Toxoplasma/metabolismoRESUMEN
BACKGROUND: Toxoplasmosis is a worldwide-distributed infection which is mostly asymptomatic but can cause serious health problems in congenitally-infected newborns and immunecompromised individuals. Research is undergoing both to improve Toxoplasma serological tests, which play the main role in laboratory diagnosis of the infection, and develop an effective vaccine to prevent the infection. Some studies showed usefulness of rhoptry protein 1 (ROP1) antigen of Toxoplasma gondii (T. gondii) in serodiagnosis of the infection and induction of protective immunity. The purpose of this study was to produce recombinant ROP1 and evaluate its antigenicity against human infected sera. METHODS: DNA encoding ROP1, amino acids 171 to 574, was obtained from T. gondii RH strain by polymerase chain reaction amplification and cloned in prokaryotic expression plasmid pET-15b. rROP1 was expressed in Escherichia coli (E. coli) and purified in a single step by immobilized metal ion affinity chromatography. RESULTS: DNA sequencing showed 99% similarity between the cloned sequence and the corresponding sequence in Gene bank. Results indicated the proper antigenicity of rROP1. Sera from Toxoplasma infected individuals specifically recognized rROP1 in Western blotting. CONCLUSION: rROP1 is antigenic toward human infected sera and can be used in studies for development of both a Toxoplasma serological test and a protective vaccine.
RESUMEN
BACKGROUND: X-ray repair cross-complementing group 1 (XRCC1) gene is a DNA repair gene and its non-synonymous single nucleotide polymorphisms (SNP) may influence DNA repair capacity which has been considered as a modifying risk factor for cancer development. METHODS: A case-control study was conducted to investigate impact of three frequently studied polymorphisms (Arg194Trp, Arg280His and Arg399Gln) on developing differentiated thyroid carcinoma (DTC). RESULTS: Increased risks for DTC were shown in homozygous (odds ratio [OR]: 3.66, 95% confidence interval [CI]: 0.38-35.60) and in dominant trait (OR: 1.22, 95% CI: 1.64-2.32) of Arg194Trp genotype. Also, for Arg280His genotype, an increased risk for DTC was shown in dominant trait (OR: 1.42, 95% confidence interval [CI]: 0.76-2.68), while a mildly reduction of risk for DTC (OR: 0.77, 95% [CI]: 0.50-1.17) was estimated in dominant Gln genotype of Arg399Gln. Considering combinatory effects of Arg194Trp and Arg280His genotypes on DTC, the calculated OR and 95% CI for being heterozygous for one of Arg194Trp or Arg280His genotypes were 1.57 and 0.90-2.74, respectively. CONCLUSION: Genotyping of codons 194, 280 and 399 in XRCC1 gene may use in risk assessment of DTC.
Asunto(s)
Diferenciación Celular , Prueba de Complementación Genética , Polimorfismo de Nucleótido Simple , Neoplasias de la Tiroides/epidemiología , Arginina/genética , Secuencia de Bases , Estudios de Casos y Controles , Cartilla de ADN , Femenino , Glicina/genética , Histidina/genética , Humanos , Irán/epidemiología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Factores de Riesgo , Neoplasias de la Tiroides/genética , Neoplasias de la Tiroides/patología , Triptófano/genéticaRESUMEN
BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) involves in folic acid metabolism which influences DNA methylation. A single nucleotide polymorphism (SNP) called 677CâT in MTHFR gene causes producing a thermolabile enzyme with reducing function and eventually defects DNA methylation. To determine association between germ-line polymorphism in MTHFR gene with differentiated thyroid carcinoma (DTC), this preliminary study was designed. METHODS: This was a case-control study of 154 DTC patients and 198 cancer free individuals. Genotyping was performed by a multiplex PCR method and the frequencies of the 677CâT SNP in cases and controls were compared. The risk estimation was done by multivariate logistic regression analysis. RESULTS: Compared to CC genotype, an increased risk of DTC for the 677CâT homozygous genotype was demonstrated (odds ratio [OR]: 2.08, 95% confidence interval [CI]: 0.82-5.25). Also, multivariate analysis demonstrated an increased risk of DTC in recessive fashion (TT vs. CC or CT) (OR: 2.38, 95% CI: 0.97-5.82). CONCLUSION: The MTHFR 677CâT homozygous variant allele may be associated with increased risk of DTC.